Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Eukaryotic Gene Expression
Fator do impacto: 1.841 FI de cinco anos: 1.927 SJR: 0.627 SNIP: 0.516 CiteScore™: 1.96

ISSN Imprimir: 1045-4403
ISSN On-line: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.2014011495
pages 281-286

Ductal Carcinoma In Situ: A Brief Review of Treatment Variation and Impacts on Patients and Society

Christine Vatovec
Rubenstein School of Environment and Natural Resources & College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont
Mujde Z. Erten
Department of Surgery, College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont; Global Health Economics Unit of the Vermont Center for Clinical and Translational Science, University of Vermont, Burlington, Vermont
Jane Kolodinsky
Department of Community Development and Applied Economics, University of Vermont, Burlington, Vermont
Phil Brown
Department of Sociology and Anthropology, Department of Health Sciences, Northeastern University, Boston, Massachusetts
Marie Wood
Department of Medicine, College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont
Ted James
Department of Surgery, College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont
Brian L. Sprague
Department of Surgery, College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont

RESUMO

Nearly 20% of all breast cancer cases are ductal carcinoma in situ (DCIS), with over 60,000 cases diagnosed each year. Many of these cases would never cause clinical symptoms or threaten the life of the woman; however, it is currently impossible to distinguish which lesions will progress to invasive disease from those that will not. DCIS is generally associated with an excellent prognosis regardless of the treatment pathway, but there is variation in treatment aggressiveness that seems to exceed the medical uncertainty associated with DCIS management. Therefore, it would seem that a significant proportion of women with DCIS receive more extensive treatment than is needed. This overtreatment of DCIS is a growing concern among the breast cancer community and has implications for both the patient (via adverse treatment-related effects, as well as out-of-pocket costs) and society (via economic costs and the public health and environmental harm resulting from health care delivery). This article discusses DCIS treatment pathways and their implications for patients and society and calls for further research to examine the factors that are leading to such wide variation in treatment decisions.

Palavras-chave: breast cancer, DCIS, treatment

Articles with similar content:

Drug Development for Metastasis Prevention
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 5-6
Steven M. Dubinett, Yari Fontebasso
Three-Dimensional Planning Tool for Breast Conserving Surgery: A Technological Review
Critical Reviews™ in Biomedical Engineering, Vol.46, 2018, issue 6
Sara P. Oliveira, Helder P. Oliveira, João F. Teixeira, Pedro F. Gouveia, Diana Veiga, Nuno L. Silva, Silvia Bessa, João P. Monteiro, Marta Reis, Maria J. Cardoso, Pedro Morgado, Hooshiar Zolfagharnasab, Manuel João Ferreira
Ethics of End-of-Life Care: The Need for Improved Communication among Physicians, Patients, and Families
Ethics in Biology, Engineering and Medicine: An International Journal, Vol.2, 2011, issue 1
D. Passigli, S. Paul, Pamela S. Saha, Subrata Saha, R. Sarkar
The Adenoma-Carcinoma Sequence and Prospects for the Prevention of Colorectal Neoplasia
Critical Reviews™ in Oncogenesis, Vol.7, 1996, issue 5-6
Seonaidh Cotton, Linda Sharp, Julian Little
Hemiplegic Shoulder Pain: Diagnosis and Management
Critical Reviews™ in Physical and Rehabilitation Medicine, Vol.20, 2008, issue 3
John M. Vasudevan, Sridhar V. Vasudevan